<div id="readability-page-1"><div>NEW YORK, May 18, 2026 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. () between November 3, 2023 and March 16, 2026, both dates inclusive (the &#34;Class Period&#34;), of the important May 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.SO WHAT: If you purchased Aldeyra securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NEXT: To join the Aldeyra class action, go to https://rosenlegal.com/submit-form/?case_id=38697 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 29, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful; and (3) as a result, defendants' statements about Aldeyra's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.To join the Aldeyra class action, go to https://rosenlegal.com/submit-form/?case_id=38697 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.Attorney Advertising. Prior results do not guarantee a similar outcome.Contact Information:Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@rosenlegal.comwww.rosenlegal.comSOURCE THE ROSEN LAW FIRM, P. A.</div></div>

ALDX

Rosen Law Firm urges investors of Aldeyra Therapeutics, Inc. who purchased securities between November 3, 2023, and March 16, 2026, to secure counsel before the May 29, 2026, lead plaintiff deadline in a securities class action. Investors may be entitled to compensation without upfront fees. The lawsuit claims misleading statements regarding clinical trial results harmed investors. For more information, contact Phillip Kim, Esq. at 866-767-3653 or via email.

PR Newswire

Aldeyra Therap

ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX